Last year alone, LLS committed $31.7 million in research dedicated to myeloma, spanning the most pioneering science including immunotherapy, genomics and personalized medicine.
"Great progress has been made in multiple myeloma research. I predict soon we will see CAR T-cell immunotherapy approved to treat this disease. LLS continues to support research efforts that will help us better understand multiple myeloma resulting in better and more effective treatments."
Louis J. DeGennaro, Ph.D., LLS President and CEO
ADVANCING THE MOST PROMISING MYELOMA RESEARCH
We are accelerating the most cutting edge research in myeloma to improve outcomes and care for patients.
C. Ola Landgren, MD, PhD. of Memorial Sloan Kettering Cancer Center
C. Ola Landgren, MD, PhD, is the attending chief of the Myeloma Service at Memorial Sloan-Kettering Cancer Center (MSKCC) and a professor of medicine at Weill Cornell Medical College in New York, NY.
Dr. Landgrenhas designed and conducted a series of studies to define biological mechanisms of transformation from myeloma precursor disease to multiple myeloma. He has launched several early interventional clinical trials for patients with high-risk smoldering myeloma with the aim to delay or prevent transformation. He aims to eradicate minimal residual disease (MRD), small traces of cancer cells that remain after therapy is completed.
LLS funding has allowed him to develop the first studies ever done with targeted immune PET imaging to show pockets of residual disease that would otherwise be missed. He credits LLS for continued funding to develop and support a clinical trial to help move treatments from the lab to patients faster.
Madhav Dhodapkar, MBBS, of Winship Cancer Institute, Emory University
Madhav Dhodapkar, M.D., of Winship Cancer Institute of Emory University, Atlanta, leads a multi-institutional, multi-disciplinary LLS Specialized Center of Research team focused on advancing new immunotherapies for patients with multiple myeloma. Their goal is to improve the effectiveness of an investigational treatment called chimeric antigen receptor (CAR) T-cell immunotherapy, that engineers the patient’s T cells to find and kill the cancer cells. The CAR-T they are studying targets a protein called BCMA found on the surface of all myeloma cells. BCMA-targeting therapies are showing tremendous promise for treating myeloma patients in clinical trials but many patients eventually relapse. Dhodapkar’s group is trying to undertand the mechanisms that cause some patients to be resistant to the treatment. They are also investigating the use of other immune cells called natural killer T cells as an alternative to T cells in the CARs. His team includes researchers at Emory as well as Fred Hutchinson Cancer Center in Seattle.
Leading Myeloma Researchers around the U.S.
Dr. Shanmugam is researching an innovative targeted therapy called venetoclax, which is showing promise in multiple myeloma and has already proven to be a game changer for some patients with chronic lymphocytic leukemia and acute myeloid leukemia.
Dr. Ghobrial is focused on transforming the treatment of myeloma through the early detection of precursor blood conditions. Her visionary research aims to uncover treatment strategies that can prevent these conditions from progressing to more serious cancers.
Dr. Yu is developing a novel immunotherapy called chimeric antigen receptor (CAR) T-cell immunotherapy for myeloma. This revolutionary therapy supercharges a patient’s own immune cells to find and attack cancer.
Dr. Orlowski is leading a world-class team of researchers to develop new immunotherapeutic and targeted approaches for the treatment of patients with high-risk subtypes of myeloma.
“What makes The Leukemia & Lymphoma Society so unique is that they really think about the impact of research on patient care. We work closely with LLS to develop and expand our ideas and LLS helps bring our work from the lab to the clinic. This makes a difference for patients every day. With support from LLS, I was able to open a clinic for patients with precursor conditions of myeloma.”